Evidence map›Paper›PMID 32697929›Full record

ArticleBlood transfusion = Trasfusione del sangue2020

RHD and RHCE molecular analysis in weak D blood donors and in patients with Rh antibodies against their own corresponding Rh antigen.

Thamy C Souza Silva, Bruno R Cruz, Sidneia S Costa, Akemi K Chiba, Melca M O Barros, Dante M Langhi, José O Bordin

Open access · greenAbstract read
In one paragraph

Article in Blood transfusion = Trasfusione del sangue, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Thamy C Souza SilvaDepartment of Clinical and Experimental Oncology, Federal University of São Paulo, UNIFESP, São Paulo, Brazil.
Bruno R CruzDepartment of Clinical and Experimental Oncology, Federal University of São Paulo, UNIFESP, São Paulo, Brazil.
Sidneia S CostaDepartment of Clinical and Experimental Oncology, Federal University of São Paulo, UNIFESP, São Paulo, Brazil.
Akemi K ChibaDepartment of Clinical and Experimental Oncology, Federal University of São Paulo, UNIFESP, São Paulo, Brazil.
Melca M O BarrosDepartment of Clinical and Experimental Oncology, Federal University of São Paulo, UNIFESP, São Paulo, Brazil.
Dante M LanghiDepartment of Clinical and Experimental Oncology, Federal University of São Paulo, UNIFESP, São Paulo, Brazil.
José O BordinDepartment of Clinical and Experimental Oncology, Federal University of São Paulo, UNIFESP, São Paulo, Brazil.
Universidade Federal de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Rh system is the largest and most polymorphic blood group system. The existence of a large number of RH alleles results in variant phenotypes that often complicate blood donor phenotyping and the distinction between auto- and allo-antibodies in recipients who have anti-Rh antibodies in the presence of their own corresponding Rh antigen. Knowledge of these variants is necessary in order to make blood transfusion safer. MATERIALS AND

methodsSamples from 48 blood donors with serological weak D and from 29 patients who had anti-Rh antibody in the presence of their own corresponding Rh antigen were evaluated molecularly for RHD and RHCE alleles using a blood-multiplex ligation-dependent probe amplification assay and Sanger sequencing.

resultsRh variants were found in 45 of the 48 blood donors: 24/45 (53%) were weak D, 2/45 (4%) partial D and 19/45 (42%) were weak and partial D. The remaining three donors (6%) did not show a mutation in the RHD allele. Among the 29 patients, 13/29 had anti-e, of whom 4/13 had genotypes that predicted a partial e antigen; 11/29 had anti-D, with 6/11 being identified as partial D; 2/29 had anti-c, of whom 1/2 was predicted to express partial c antigen; 4/29 who had anti-E and 4/29 who had anti-C did not show mutations in RHCE*C or RHCE*E. DISCUSSION: It was possible to find individuals with clinically significant Rh phenotypes due to the weak reactivity of the D antigen, detected through serological tests in blood donors. In patients, when found with the anti-Rh antibody in the presence of the same Rh antigen, it is difficult to distinguish an auto-antibody from an allo-antibody by serological tests; in these cases, molecular methods (genotyping) can help us to determine whether there are changes in the RH alleles and to discover the nature of the antibody (allo or auto).

Indexed as

Blood DonorsGenotypeMutationRh-Hr Blood-Group SystemFemaleHumansIsoantibodiesMaleIsoantibodiesRHCE protein, humanRh-Hr Blood-Group SystemRho(D) antigen

Identifiers

PMID32697929
PMCPMC7375890
OpenAlexW3044949938

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.